AG/RES. 2493 (XXXIX-O/09) Observations and Recommendations on the Annual Report of the Inter-American Drug Abuse Control Commission

Bureau of Western Hemisphere Affairs
June 4, 2009

Organization of American States
(Adopted at the fourth plenary session, held on June 4, 2009)


HAVING SEEN the observations and recommendations of the Permanent Council (AG/doc.4992/09 add. 1) on the Annual Report of the Inter-American Drug Abuse Control Commission to the General Assembly (CP/doc.4395/09 corr. 1);

TAKING INTO ACCOUNT its resolution AG/RES. 2378 (XXXVIII-O/08), “Observations and Recommendations on the Annual Report of the Inter-American Drug Abuse Control Commission,” and other resolutions related to the topic;

MINDFUL of the need for strengthening efforts against the cultivation of illicit crops, illicit drug trafficking, and related crimes, such as money laundering, the illegal distribution via the Internet of internationally controlled licit substances, and the illicit diversion of pharmaceutical products and chemical precursors;

MINDFUL ALSO of the need to make greater headway with reduction in the demand for illicit drugs and the abuse of pharmaceutical products with psychoactive properties;

RECOGNIZING that drug abuse is a public health problem that affects society as a whole and that the member states attach great importance to early prevention of drug abuse in the family, school, workplace, and community, including programs that strengthen values and life skills in children and youth;

MINDFUL that the treatment and rehabilitation of drug abusers as well as their reintegration into society should be essential elements of national health care systems;

MINDFUL ALSO of the need for increased international cooperation and technical assistance to member states, to enhance their capacity to deal with the world drug problem and its related crimes;

DEEPLY CONCERNED over the existence, in some countries, of armed groups related to drug trafficking, giving rise to conditions that can destabilize the institutional order and undermine democratic governance of those states;

RECOGNIZING the links that may exist between illicit drug trafficking and other modalities of transnational organized crime;

CONSIDERING that, with the adoption of the 34 national reports on implementation of the recommendations of the Fourth Evaluation Round 2005-2006, the Multilateral Evaluation Mechanism (MEM) concluded the last phase of this evaluation round;

NOTING WITH SATISFACTION that the Inter-American Drug Abuse Control Commission has strengthened its cooperation and exchange of information with all pertinent subregional, inter-American, and international bodies; and

RECOGNIZING the significance of the 1998 United Nations General Assembly Special Session (UNGASS) goals and targets, and the important contribution that the MEM process made to the hemispheric evaluation of these goals and objectives 10 years after this Special Session,


1. To thank the Inter-American Drug Abuse Control Commission (CICAD) for the presentation of its 2008 annual report (CP/doc.4395/09 corr. 1) to the General Assembly and to congratulate it on the progress made in all aspects of the control of narcotic drugs and psychotropic substances.

2. To reaffirm its commitment to the Multilateral Evaluation Mechanism (MEM) as an objective instrument for measuring the progress made by member states in addressing the worldwide drug problem, identifying vulnerabilities and areas for improvement, and strengthening hemispheric solidarity and cooperation.

3. To instruct the CICAD Executive Secretariat to continue to provide technical assistance, training, and support to member states in the areas of drug demand reduction, supply reduction, drug-related research and information systems, alternative, integral, and sustainable development, institution-building, money-laundering control, and education, with a view to strengthening member states’ capacities in these fields, and in particular to:

a. Partner with universities in the Hemisphere to introduce drug-related educational content into undergraduate and graduate curricula in appropriate disciplines;

b. Continue to promote the adoption of court-supervised treatment for drug-dependent petty offenders, in accordance with the legislation of each country;

c. Develop and carry out capacity-building programs for health-related professionals in priority areas of demand reduction and other fields;

d. Continue to provide technical assistance and training to member states to strengthen their capacity to combat illicit drugs and their cultivation, production, manufacture, distribution, and trafficking, as well as the chemicals used to produce them, with particular emphasis on those member states with special needs;

e. Help member states to respond to new challenges they face with respect to routes and methods used to transport illicit drugs, as well as new trends and threats such as synthetic drugs, diversion of pharmaceuticals, and the illicit sale of drugs over the Internet;

f. Continue to provide technical assistance to member states regarding alternatives to illicit crops, paying particular attention to those states that are most vulnerable to this threat;

g. Continue to provide member states with technical assistance and support to confront the issue of money laundering, with a particular focus on improving coordination among the various agencies involved in the process;

h. Support member states in their efforts to improve their capacity to carry out scientific research, and data gathering and analysis, with particular emphasis on building drug-information systems and enhancing national drug observatories;

i. Continue to provide technical assistance, generating knowledge and good practice models in institution-building; and develop capacity-building programs and articulate horizontal cooperation strategies to increase the capacity of the member states, their institutions, civil society, and communities to respond to the drug phenomenon; and

j. Provide technical assistance and training to member states to strengthen all aspects of their national and municipal drug control systems, and in particular to national drug commissions.